Connect with us
The Minister reminded that the Inveat Plan will involve an overall investment of more than $900.5 million (€795 million) throughout Spain, which will enable the renewal...
Looking ahead to 2022, ZeClínics is preparing an artificial intelligence (AI) platform that collects and interprets data to identify potential therapeutic targets. To implement this novelty,...
White Bridge Investments currently holds 70% of the shares of Biofarma Group, while the remaining 30% belongs to Germano Scarpa and Gabriella Tavasani. White Bridge had...
Peptomyc has focused its project on the development of a new generation of cell-penetrating peptides (CPP) targeting the Myc oncoprotein, with the aim of treating different...
Qmenta needs $10 million to further expand. For the time being, the company's main front will remain neurological diseases. Currently, one billion people worldwide suffer from...
The blood-brain barrier is a major hurdle in treating a whole range of diseases affecting the CNS. While it serves a vital role in protecting against...
Stocks like BB Biotech should be treated with caution. Nevertheless, there is a quite realistic chance that investors will receive a higher dividend from BB Biotech....
Estimated as a $3 billion opportunity for Bioasis Technologies, the company's xB3 platform is set to revolutionize the treatment of neurological disease. The technology helps deliver...
Aortyx has received a $2.8 million (€2.5 million) grant from the European Commission. Prior to this investment, the company was already recognized and funded with more...
The negative variation of the Spanish pharmaceutical sector contrasts with the positive performance of the Ibex35, which recorded a rise of 8% at the close of...
 |
|
 |  |
 |
|